Clinical Trial Detail

NCT ID NCT02228369
Title Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer (BLOOM)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors AstraZeneca
Indications

lung non-small cell carcinoma

Therapies

Osimertinib

AZD3759

Age Groups: adult senior

No variant requirements are available.